CN107365771A - For suppressing the oligonucleotide molecule and its composition set of CTNNB1 target genes mRNA expression - Google Patents

For suppressing the oligonucleotide molecule and its composition set of CTNNB1 target genes mRNA expression Download PDF

Info

Publication number
CN107365771A
CN107365771A CN201710754584.5A CN201710754584A CN107365771A CN 107365771 A CN107365771 A CN 107365771A CN 201710754584 A CN201710754584 A CN 201710754584A CN 107365771 A CN107365771 A CN 107365771A
Authority
CN
China
Prior art keywords
sirna
seq
complete
target gene
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710754584.5A
Other languages
Chinese (zh)
Other versions
CN107365771B (en
Inventor
张必良
杨秀群
丹米其·萨玛斯基
克雷格·梅洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agna Biopharmaceutical Co ltd
Original Assignee
Guangzhou Ribobio Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ribobio Co ltd filed Critical Guangzhou Ribobio Co ltd
Priority to CN201710754584.5A priority Critical patent/CN107365771B/en
Publication of CN107365771A publication Critical patent/CN107365771A/en
Application granted granted Critical
Publication of CN107365771B publication Critical patent/CN107365771B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of oligonucleotide molecule and its composition set for being used to suppress CTNNB1 target genes mRNA expression.The invention provides siRNA, the positive-sense strand being made up of 19 27 nucleotides and formed with the antisense strand of its reverse complemental；In the positive-sense strand from 5 ' ends 59 continuous nucleotides and 59 continuous nucleotides are 2 ＇-ribose modified nucleotide from 3 ' ends.SiRNA molecule mixture can influence at least 50%, 55%, 60%, 65%, 70% in the present invention, 75%th, the expression of 80%, 85%, 90% cell target gene, inhibiting rate are at least 45%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%.

Description

For suppressing the oligonucleotide molecule of CTNNB1 target genes mRNA expression and its into set group Compound
The application be the applying date be 2016-08-18, Application No. 201610687850.2, entitled " one kind is used for The divisional application of the application for a patent for invention of the oligonucleotide molecule and its composition set of suppression target gene mRNA expression ".
Technical field
The present invention relates to biology field, more particularly to a kind of oligonucleotide point for being used to suppress target gene mRNA expression Son and its composition set.
Background technology
From Andrew Fire and Craig Mello et al. 1998 in nematode (Caenorhabditis elegans) After finding RNAi phenomenons, Tuschl and Phil Sharp et al. confirmation in 2001 in mammal there is also RNAi first, The researchs such as mechanism principle, gene function and clinical practice on RNAi achieve a series of progress.RNAi is not only being defendd Virus infection, the jump of anti-rotation stand etc. play in a variety of body protective mechanism key effect (Huntvagner et al, 2001； Tuschl,2001；Waterhouse et al,2001；Zamore 2001), its Related product is also very promising candidate Medicine.
Elbashir et al. had found that siRNA suppresses the silence of specific gene in mammalian cell in 2001, studied table Bright siRNA can be specifically the complementary said target mrna of same sequence combine, and make its degraded.The double-stranded RNA of long segment is by Dicer cleavages Into 21-23 bases longs short-movie section RNA, the chain combined in two of which chain with said target mrna is referred to as antisense strand or guiding chain, separately One chain is referred to as positive-sense strand or passerby chain.Research finds that the siRNA of iii vitro chemical synthesis similarly plays RNAi after entering cell Effect, and effectively reduce immune response caused by long-chain RNA.
But because siRNA validity is influenceed by many factors such as sequence-specific, target cell specificity, target spot, it is based on The siRNA that existing design principle obtains not is each to be attained by effective silencing efficiency；The siRNA being typically designed there are about More than 50% has the effect of silence said target mrna, and only 25% siRNA has more than 75% silencing efficiency, therefore follow-up pair sets The siRNA of meter synthesis also needs to experimental verification, screening or optimization, time-consuming effort；It is a kind of general, efficient, quick based on this RNAi technology is urgently developed with product.
The content of the invention
It is an object of the present invention to provide a kind of siRNA for suppressing or reducing CTNNB1 expression of target gene.
SiRNA provided by the invention, formed by positive-sense strand and with the antisense strand of its reverse complemental (being completely reversed complementation)；
The positive-sense strand is made up of 19-27 nucleotides, and the positive-sense strand from 5 ' ends 5-9 continuous nucleotide and 5-9 continuous nucleotide carries out the modification of 2 ＇-O- ribose from 3 ' ends.
The antisense strand and the section reverse complemental on the target gene, the target gene is CTNNB1；
The base composition sequence of the positive-sense strand is selected from SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13；
The base composition sequence of the antisense strand is selected from SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14.
SiRNA is combined by its antisense strand with the target sequence reverse complemental on target gene；
In some embodiments of invention, a non-natural nucleotides is comprised at least in siRNA molecule, is such as repaiied through chemistry The nucleotides of decorations, the preferably chemical modification in positive-sense strand or just area.In certain embodiments, the 2 ＇-O- ribose modification of ribose Specially 2 ＇-O- methyl are modified, the modification of 2 ＇-O- fluoro, 2 ＇-MOE modifications.The positive-sense strand modification of the present invention can be played：(1) strengthen SiRNA molecule stability；(2) missing the target property of siRNA molecule is reduced；(3) siRNA molecule specificity is improved；(4) immune activation is reduced The effect such as reaction.
In above-mentioned siRNA, the positive-sense strand is made up of 24,25 or 26 nucleotides；
Or, the positive-sense strand 6 or 7 or 8 continuous nucleotides and 6 or 7 or 8 continuous kernels from 3 ' ends from 5 ' ends Thuja acid carries out the modification of 2 ＇-O- ribose.
In above-mentioned siRNA, the 2 ＇-O- ribose is modified to 2 ＇-O- methyl (2 ＇-O-Me) modification, 2 ＇-O- fluoro are modified, Or 2 ＇-MOE modification.
Another object of the present invention is to provide a kind of complete siRNA for suppressing or reducing expression of target gene.
Complete siRNA provided by the invention, including the siRNA that at least five is above-mentioned.
Each siRNA corresponds to the different target sequences of same target gene.
In above-mentioned complete siRNA, the complete siRNA is made up of 5,6,7,8,9 or 10 siRNA.
In above-mentioned complete siRNA, the amount of the material of single siRNA molecule can be random in the complete siRNA, appoint The amount ratio of 2 siRNA material is 1:1-1:5；It is preferred that the amount of the material of single siRNA molecule equal 1:1.
1) or 2) another object of the present invention is to provide another following material.
Or 2) 1) material provided by the invention：
1) suppress or reduce the reagent of expression of target gene, it is following A or B：
A includes above-mentioned siRNA and transfection reagent；
B includes above-mentioned complete siRNA and transfection reagent；
2) suppress or reduce the kit of expression of target gene, it includes above-mentioned siRNA or above-mentioned complete siRNA or described Reagent.
In above-mentioned substance, total concentration of all siRNA molecules in the reagent is 2-100nM in the complete siRNA； Each concentration of the siRNA molecule in the reagent is 10-20nM；
The application of above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material in suppressing or reducing expression of target gene And the scope of protection of the invention；
Or above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material are suppressing or are reducing the expression of cell target gene In application be also the scope of protection of the invention；
Or above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material are preparing suppression or are reducing expression of target gene production Application in product is also the scope of protection of the invention；
Or above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material are preparing suppression or are reducing cell target gene The application of product is also the scope of protection of the invention in expression；
Or above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material are preparing prevention or alleviation or treated by target base Because the application in the product in disease caused by expression is also the scope of protection of the invention.
Method provided by the invention, comprises the following steps：Will suppress or reduce expression of target gene siRNA positive-sense strand from 5 ' ends play 5-9 continuous nucleotide and 5-9 continuous nucleotide carries out the modification of 2 ＇-O- ribose from 3 ' ends；
The siRNA forms by positive-sense strand and with the antisense strand of its reverse complemental；
The positive-sense strand is made up of 19-27 nucleotides；
The antisense strand and the section reverse complemental on the target gene.
Or the 2 ＇-O- ribose modification is specially the modification of 2 ＇-O- methyl, the modification of 2 ＇-O- fluoro or 2 ＇-MOE modifications.
4th purpose of the invention is to provide a kind of product.
Product provided by the invention, including above-mentioned siRNA or above-mentioned complete siRNA or above-mentioned material；
And/or the product has following 1) -3) at least one of function：
1) suppress or reduce expression of target gene；
2) suppress or reduce the expression of cell target gene；
3) prevention or alleviation or treatment disease as caused by expression of target gene.
In above-mentioned, the target gene is tumour, cancer, angiocardiopathy, inflammation, infectious disease or rare sick related gene；
Or, the tumour, cancer, angiocardiopathy, inflammation, infectious disease or rare sick related gene are specially CTNNB1；
The cell is specially vertebrate cells, mammalian cell, primates zooblast, human cell；
Or, target gene unconventionality expression (expression is higher than normal subjects) or have gene defect (such as chromosome is different Often or gene mutation) cancer cell, tumour cell, inflammatory cell, blood cell, leucocyte, brain cell, liver cell, pneumonocyte, Nephrocyte, mammary glandular cell, cervical cell, endothelial cell, nerve cell, Deiter's cells；
Or, the cell is specially HeLa, 293T, A549 or HUVEC cell；
Or, the product is specially medicine.
Above-mentioned target gene can be tumour or cancer related gene, preferably CTNNB1 genes.
SiRNA corresponding to above-mentioned target gene is as follows：
Target gene is CTNNB1, and complete siRNA corresponding to it is RB-CTN-D1, RB-CTN-D2, RB-CTN-D3, RB- At least six in CTN-D4, RB-CTN-D5, RB-CTN-D6, RB-CTN-D7.
Present invention additionally comprises a kind of method for reducing the expression of cell target gene, methods described is including the use of above-mentioned mixing Thing, method include a) obtaining siRNA molecule or its mixture, and the siRNA molecule mixture comprises at least 5,6,7,8,9,10 Individual siRNA；B) siRNA molecule mixture is delivered into cell.
The present invention is by introducing siRNA molecule or its mixing to cell in siRNA molecule mixture (complete siRNA) Thing, suppress the expression of target gene；Introducing can be to be introduced directly into or introduce indirectly, other known in addition to using transfection reagent Various all to use the siRNA molecule delivering such as mode of cell, such as injection, (carrier can be plasmid or disease for carrier transfection Poison), electroporation, liposome transfection etc..
" complementation " refers to the ability matched between core base.
Also the length of nucleotides or RNA molecule chain can be represented in the present invention with base or bases longs.
The tolerance mispairing of the siRNA molecule of the present invention is at least 1-5 nucleotides, and its preferred tolerant position is single-stranded or double Chain end, the base number of tolerance are influenceed by complementary section length." mispairing " refers to that core base can not match.
The preferred solid-phase synthesis of siRNA molecule mixture obtains, and can also be synthesized by the method for transcribing or other method.
The kit of the present invention may also include buffer solution, label in addition to siRNA molecule and/or siRNA molecule mixture (label can be dyestuff, radioactive marker substance or fluorescence labeling material, and the position of mark can be in antisense strand or positive-sense strand End), transfection reagent, container, test tube, reagent of annealing, control siRNA (including NC controls, N controls) etc.；In kit SiRNA molecule mixture is placed in a vessel after can also can be combined by single packing；Kit components can be frozen Dry powder or solution.
The experiment proves that single siRNA molecule stability is good, external or internal suppression examination is on the one hand improved To the resistance of nuclease in testing；On the other hand be advantageous to store and transport；The effect of missing the target of siRNA molecule is reduced simultaneously.Into It is even more a kind of general, effectively and rapidly RNAi instruments to cover siRNA, it is advantageous that：(1) more than 60% inhibiting rate is can ensure that, More than 75% siRNA molecule mixture can reach more than 75% inhibiting rate, and more than 50% siRNA molecule mixture can reach To more than 85% inhibiting rate, relative to single siRNA molecule, the probability of silence and the efficiency of silence are integrally improved；Existing Have in technology, the probability that the siRNA being typically designed only has 50% can suppress expression of target gene, and only 25% siRNA can reach More than 75% inhibiting rate.(2) particular design is not required to, is subsequently not required to screen siRNA, optimizes, or its effect is carried out Experimental verification, it is time saving and energy saving.(3) solve in different cell lines, different transfection reagents processing when, siRNA effect it is inconsistent The problem of, can in multiple cell lines effective reticence target gene, and do not influenceed by transfection reagent.(4) single siRNA is enhanced The Gene silencing efficacy of molecule, serve the effect of Synergistic.(5) effect of missing the target of siRNA molecule is reduced.
SiRNA molecule mixture can influence at least 50%, 55%, 60%, 65%70%, 75%, 80% in the present invention, 85%, the expression of 90% cell target gene, inhibiting rate is at least 45%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%.Can be true when the siRNA molecule mixture of the present invention is in different cell lines, different transfection reagents are handled Protect at least 60% target gene inhibition." suppression " of the present invention or similar expression can refer to RNA or protein level or related raw Change the reduction of the expressing of index, activity or index with respect to negative control.
Brief description of the drawings
Fig. 1 is siRNA vitro stability measurement results.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc., unless otherwise specified, are commercially obtained in following embodiments.
The preparation of embodiment 1, siRNA
All single siRNA of design can target all transcripts of target gene, and design method is with reference to Elbashir et al.2002；Paddison et al.2002；Reynoldset al.2004；Ui-Tei et al.2004 et al. method (Elbashir,S.M.,Harborth,J.,Weber,K.,and Tuschl,T.2002.Analysis of gene function in somatic mammalian cells using small interfering RNAs.Methods 26: 199–213；Paddison,P.J.,Caudy,A.A.,Bernstein,E.,Hannon,G.J.,and Conklin, D.S.2002.Short hairpin RNAs(shRNAs)induce sequence-specific silencing in mammalian cells.Genes&Dev.16:948–958；Reynolds,A.,Leake,D.,Boese,Q.,Scaringe, S.,Marshall,W.S.,and Khvorova,A.2004.Rational siRNA design for RNA interference.Nat.Biotechnol.22:326–330；Ui-Tei,K.,Naito,Y.,Takahashi,F., Haraguchi,T.,Ohki-Hamazaki,H.,Juni,A.,Ueda,R.,and Saigo,K.2004.Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.Nucleic Acids Res.32:936–948)；To ensure siRNA specificity, BLAST is used (Basic Local Alignment Search Too,http://www.ncbi.nlm.gov)) analytical sequence homogeneity (identity), the selection sequence minimum with other sequences homogeneity.
The SS positive-sense strands and formed with the antisense strand AS of its reverse complemental that siRNA is made up of 25 nucleotides, and be flat end End；
Each siRNA is combined by its antisense strand with the target sequence reverse complemental on the target gene；
AS chains and SS chains are completely reversed complementation, and AS chains are completely reversed complementation with the target sequence on target gene, and SS's is last from 5 ' 7 continuous nucleotides are held and 7 continuous nucleotides are modified by 2 ＇-O-Me from 3 ' ends.
Target gene is as shown in table 1, and siRNA particular sequences are as shown in table 2 corresponding to target gene.
Table 1 is target gene
Table 2 is siRNA molecule sequence table
In above-mentioned table, mA, mU, mC and mG are respectively that U, 2 ＇-O-Me are modified after A, 2 ＇-O-Me modification after 2 ＇-O-Me are modified G after C and 2 ＇-O-Me modifications afterwards.
Embodiment 2, siRNA cellular levels suppress experiment
The individually transfection HeLa cells of siRNA corresponding to the CTNNB1 target genes shown in table 2 prepared by embodiment 1 (deriving from ATCC), it is specific as follows：
1st, LF2K is transfected
100 μ L LF2K rotaring redyeing systems：1 μ L LF2K (Invitrogen, 11668019), 5 μ L siRNA are (final concentration of 100nM) and 94 μ L Opti-MEM cell culture mediums (Thermo Fisher Scientific, 31985070).
Above-mentioned siRNA is respectively TP53, BIRC5, CTNNB1, COPS5, STAT3, VEGFA, KRAS prepared by embodiment 1 SiRNA corresponding to target gene.
HeLa cells are cultivated on Tissue Culture Plate, then above-mentioned 100 μ L rotaring redyeing systems are added into each hole, transfect 48h, Obtain transfecting the cell that different target genes correspond to siRNA.
2nd, RT-PCR detects inhibiting rate
After transfecting 48h, collect and transfect the cell that different target genes correspond to siRNA, the extraction of Trizol methods RNA, Reverse Transcription mix reverse transcription reagent box is used for reverse transcription (Guangzhou Ribo Bio Co., Ltd., C10170), obtains The cDNA of siRNA cell is corresponded to the different target genes of transfection.Using cDNA as template, the target base corresponding to the siRNA shown in table 3 The primer pair of cause carries out RT-PCR amplifications, and reference gene (Forward is used as using the house-keeping gene actin of people:5- TCAAGATCATTGCTCCTCCTGAG-3(SEQ ID NO.15)；Reverse:5-ACATCTGCTGGAAGGTGGACA-3 SEQ ID NO.16), carried out using Real-timePCR kits SYBRPremix (2 ×) (BIO-RAD 750000131) glimmering in real time Fluorescent Quantitative PCR reacts.(each individually sample has 3 repetitions in transfection, each in qPCR for 9 repetitions of one sample 3 multiple holes are done in repetition) Ct errors ± 0.5, then carry out relative quantitative assay with CFX2.1.SPSS19.0 data statistics is soft Part data analysis, data are its average value in table, and P values are equal<0.05.
NC negative control groups：The siRNA of transfection is unrelated non-specific siRNA,
5'UUCUCCGAACGUGUCACGU dTdT3'(SEQ ID NO.17)
5'ACGUGACACGUUCGGAGAA dTdT3'(SEQ ID NO.18)
N blank control groups：Normal cell, no siRNA transfections.
Real-Time PCR inhibiting rate calculations：
Inhibiting rate=The mRNA relative expression levels of NC negative control group mRNA relative expression levels-siRNA groups
NC negative control group mRNA relative expression levels
NC negative control groups mRNA relative expression levels are 1.
Table 3 is primer sequence
As a result it is as shown in table 4, it can be seen that for CTNNB1 target genes, the siRNA of design serves suppression target gene The effect of expression.
Table 4 is that the inhibiting rate of single siRNA in HeLa cells compares
Target gene siRNA D1 D2 D3 D4 D5 D6 D7
CTNNB1 88 90 90 89 87 91 62
D1-D7 in above-mentioned table is respectively 7 siRNA for CTNNB1 target genes.
The preparation of embodiment 3, complete siRNA
1st, design principle
Complete siRNA is made up of 5-10 siRNA molecule；
The SS positive-sense strands and formed with the antisense strand AS of its reverse complemental that each siRNA is made up of 25 nucleotides, and be Flat end；Each siRNA combines by the way that the target sequence on its antisense strand and target gene is complementary；
AS chains and SS chains are completely reversed complementation, and AS chains are completely reversed complementation with the target sequence on target gene, and SS's is last from 5 ' 7 continuous nucleotides are held and 7 continuous nucleotides are modified by 2 ＇-O-Me from 3 ' ends.
Target gene is as shown in table 1, and siRNA is as shown in table 2 corresponding to target gene.
The complete siRNA of target gene can include 5,6,7 or 10 siRNA, and packet situation is as shown in table 5.
The complete siRNA compositions of the target gene of table 5
Respectively by above-mentioned complete siRNA groups RM-2 (7 siRNA are mixed), RM-3 (6 siRNA are mixed), in it is each SiRNA requires mixing according to the packet shown in table 5, and each siRNA is equimolar ratio mixing.
Embodiment 4, complete siRNA suppress the research of expression of target gene
The following examples exemplified by the complete siRNA groups RM-2 (7 siRNA mixing) in table 5 with being tested：
First, complete siRNA groups RM-2 is compared with single siRNA molecule is to HeLa cell target gene inhibiting rates
It is thin that complete siRNA groups RM-2 corresponding to CTNNB1 target genes in embodiment 3 shown in table 5 is transfected into HeLa respectively Born of the same parents, method is same as Example 2, wherein, the total concentration of all siRNA molecules is 100nM in RM-2 mixtures, and each SiRNA molecule is the amount mixing of the material waited.
To transfect single siRNA molecule as control, wherein, the concentration of single siRNA molecule is 100nM.
Complete siRNA groups RM-2 inhibiting rates and single siRNA inhibiting rates result are as shown in table 6, it can be seen that for 7 Target gene, complete siRNA groups RM-2 inhibitions are all higher than 90%；And 7 lists of the same concentration of complete siRNA groups RM-2 Individual siRNA molecule is compared, and serves the effect of Synergistic.
RM-2 and single siRNA comparison in table 6HeLa cells
Gene RM-2 D1 D2 D3 D4 D5 D6 D7
CTNNB1 93 88 90 90 89 87 91 62
D1-D7 in above-mentioned table is respectively 7 siRNA corresponding to CTNNB1 target genes, and RM-2 is corresponding for each target gene 7 siRNA biased sample.
2nd, complete siRNA RM-2 inhibition compares in different cell lines
Complete siRNA groups RM-2 corresponding to CTNNB1 target genes in embodiment 3 shown in table 5 is transfected into 4 kinds of differences respectively Cell line (human embryonic kidney cells 293T, cervical cancer cell HeLa, non-small cell lung cancer cell A549 and Human umbilical vein endothelial cells Cell is observed after HUVEC (deriving from ATCC) inoculated and cultureds 24h, it is in good condition to start to transfect.
1st, transfect
(1) 50 μ L riboFECT rotaring redyeing systems, 5 μ L riboFECTTMCP Reagent (the sharp rich biotechnologies in Guangzhou Co., Ltd, C10511-05), complete siRNA groups RM-2 prepared by 5 μ L embodiments 3 (all siRNA total concentration is 100nM) With 40 μ L riboFECTTMCPBuffer (Guangzhou Ribo Bio Co., Ltd., C10511-05).
(2) 100 μ L LF2K rotaring redyeing systems：1 μ L LF2K (Invitrogen, 11668019), prepared by 5 μ L embodiments 3 Complete siRNA groups RM-2 (all siRNA total final concentration of 100nM) and 94 μ L Opti-MEM cell culture mediums (Thermo Fisher Scientific, 31985070).
To be separately added into each hole of 4 kinds of different cell line culture plates above-mentioned 50 μ L riboFECT rotaring redyeing systems or 100 μ L LF2K rotaring redyeing systems, cell, the extraction of Trizol methods RNA, Reverse Transcription are collected after transfecting 48h Mix reverse transcription reagent box obtains cDNA for reverse transcription (Guangzhou Ribo Bio Co., Ltd., C10170).
2nd, RT-PCR detects inhibiting rate
Method is same as Example 2.
As a result as shown in table 7, compareed with respect to NC, for different target genes, in different cell line, using different Transfection reagent, RM-2 mixtures can reach more than 60% inhibition.
RM-2 inhibiting rate compares (%) in 7 different cell lines of table
3rd, in HeLa cells RM-2 mixtures compared with the mixture histamine result of the siRNA molecule of usual structure
Two target genes of SOD1, EIF4E are chosen, compare the siRNA molecule of its corresponding RM-2 mixture and usual structure Mixture in HeLa cells inhibition.
The usual structure siRNA of above-mentioned each gene nucleotide sequence RM-2 corresponding with each gene prepared by embodiment 3 The difference is that each nucleotides is modified without 2 '-O-Me in generally structure siRNA, length (removes positive-sense strand respectively for 19bp 6 nucleotides that 6 nucleotides and antisense strand 3 ' at 5 ' ends are held), there are 2 dTdT pendencys, remaining all same in end.
Method is identical with above-mentioned one, the difference is that complete siRNA groups corresponding to SOD1, EIF4E prepared by embodiment 3 RM-2 transfection HeLa cells (M).
To transfect the mixture of the siRNA molecule of usual structure corresponding to SOD1, EIF4E as control (S).Transfection reagent is LF2K。
In above-mentioned transfection, siRNA total concentration is 100nM.
As a result as shown in table 8,2 target genes of pin, the inhibition of the mixture of RM-2 structures is better than usual structure The mixture of siRNA molecule.
RM-2 modifies results contrast in table 8HeLa cells
4th, the inhibition of the complete siRNA transfection HeLa cells of different groups compares
This 2 target genes of selection SOD1, MYC, more different complete siRNA groups inhibitions in HeLa cells.
Method is identical with above-mentioned one, the difference is that complete siRNA groups RM- corresponding to SOD1, MYC prepared by embodiment 3 2nd, RM-3 and RM-6 difference transfection HeLa cell.Transfection reagent is LF2K.
As a result as shown in table 9,
The siRNAs mixtures that the different siRNA bars numbers of table 9 mix
Gene RM-1 (5) RM-3 (6) RM-2 (7) RM-6 (10)
SOD1 80 82 85 91
MYC 63 66 74 80
As a result show, mixture RM-1, RM-3, RM-2, RM-6 can play a part of efficiently suppressing several genes.
Embodiment 5, vitro stability measure
Each siRNA RB-KRA-D1, RB-TP5-D6, RB-EIF-D3 such as are added at the body after being diluted to 5 μM without RNase water Long-pending fresh rat serum (for Shanghai Yuan Mu bio tech ltd product), then 37 DEG C be incubated 6 hours after sample into Row electrophoresis observation difference siRNA integrality.
It is as a result as shown in Figure 1, it will be seen that, siRNA is stable in serum, it is contemplated that it has more preferable effect in vivo.
Other siRNA Stability Determination experimental result is identical, and specific figure omits.
Each technical characteristic of the embodiment can be combined arbitrarily, to make description succinct, not to above-described embodiment In each technical characteristic it is all possible combination be all described, as long as however, lance is not present in the combination of these technical characteristics Shield, all it is considered to be the scope of this specification record.
Embodiment described above only expresses the several embodiments of the present invention, and its description is more specific and detailed, but simultaneously Can not therefore it be construed as limiting the scope of the patent.It should be pointed out that come for one of ordinary skill in the art Say, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the protection of the present invention Scope.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Sequence table
<110>Guangzhou Ribo Bio Co., Ltd.
<120>For suppressing the oligonucleotide molecule and its composition set of CTNNB1 target genes mRNA expression
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 1
caguuauggu ccaucagcuu ucuaa 25
<210> 2
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 2
uuagaaagcu gauggaccau aacug 25
<210> 3
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 3
uccucagaug gugucugcua uugua 25
<210> 4
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 4
uacaauagca gacaccaucu gagga 25
<210> 5
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 5
cagauccaag ucaacgucuu guuca 25
<210> 6
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 6
ugaacaagac guugacuugg aucug 25
<210> 7
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 7
gaaucuuuca gaugcugcaa cuaaa 25
<210> 8
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 8
uuuaguugca gcaucugaaa gauuc 25
<210> 9
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 9
aggcuacugu uggauugauu cgaaa 25
<210> 10
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 10
uuucgaauca auccaacagu agccu 25
<210> 11
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 11
gcagcugcuu uauucuccca uugaa 25
<210> 12
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 12
uucaauggga gaauaaagca gcugc 25
<210> 13
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 13
ggcuuggaau gagacugcug aucuu 25
<210> 14
<211> 25
<212> RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 14
aagaucagca gucucauucc aagcc 25
<210> 15
<211> 23
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 15
tcaagatcat tgctcctcct gag 23
<210> 16
<211> 21
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 16
acatctgctg gaaggtggac a 21
<210> 17
<211> 21
<212> DNA/RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 17
uucuccgaac gugucacgut t 21
<210> 18
<211> 21
<212> DNA/RNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 18
acgugacacg uucggagaat t 21
<210> 19
<211> 19
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 19
gctcgggatg ttcacaacc 19
<210> 20
<211> 19
<212> DNA
<213>Artificial sequence (2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 20
ccctgcagct actctttgg 19

Claims (10)

1. it is a kind of suppress or reduction CTNNB1 expression of target gene siRNA, it is characterised in that by positive-sense strand and with its reverse complemental Antisense strand composition；
The positive-sense strand is made up of 19-27 nucleotides, and positive-sense strand 5-9 continuous nucleotide and from 3 ' from 5 ' ends Play 5-9 continuous nucleotide and carry out the modification of 2 ＇-O- ribose in end；
The antisense strand and the section reverse complemental on the target gene；
The base composition sequence of the positive-sense strand is selected from SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13；
The base composition sequence of the antisense strand is selected from SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14.
2. siRNA according to claim 1, it is characterised in that：
The positive-sense strand is made up of 24,25 or 26 nucleotides；
The positive-sense strand 7 continuous nucleotides and 7 continuous nucleotides carry out 2 ＇-O- ribose from 3 ' ends from 5 ' ends Modification.
3. siRNA according to claim 2, it is characterised in that：
2 ＇-O- the ribose is modified to the modification of 2 ＇-O- methyl, the modification of 2 ＇-O- fluoro or 2 ＇-MOE modifications.
4. it is a kind of suppress or reduction CTNNB1 expression of target gene complete siRNA, including at least six claim 1-3 it is any Described siRNA.
5. complete siRNA according to claim 4, it is characterised in that：The complete siRNA is by 6,7,8,9 or 10 SiRNA is formed.
6. complete siRNA according to claim 5, it is characterised in that：Wantonly 2 siRNA materials in the complete siRNA Amount is than being 1:1-1:5.
7. complete siRNA according to claim 6, it is characterised in that：Wantonly 2 siRNA materials in the complete siRNA Amount is than being 1:1.
8. suppress or reduce the kit of CTNNB1 expression of target gene, it is characterised in that it is any described that it includes claim 1-3 SiRNA or any described complete siRNA of claim 4-7.
9. kit according to claim 8, it is characterised in that：All siRNA molecules are in reagent in the complete siRNA In total concentration be 2-100nM.
10. any described complete siRNA of any described siRNA or claim 4-7 of claim 1-3 prepare prevention or Alleviate or treat the application in the medicine in the disease as caused by CTNNB1 expression of target gene.
CN201710754584.5A 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting CTNNB1 target gene mRNA expression and its set composition Active CN107365771B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710754584.5A CN107365771B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting CTNNB1 target gene mRNA expression and its set composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710754584.5A CN107365771B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting CTNNB1 target gene mRNA expression and its set composition
CN201610687850.2A CN106047879A (en) 2016-08-18 2016-08-18 Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201610687850.2A Division CN106047879A (en) 2016-08-18 2016-08-18 Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof

Publications (2)

Publication Number Publication Date
CN107365771A true CN107365771A (en) 2017-11-21
CN107365771B CN107365771B (en) 2020-11-10

Family

ID=57194772

Family Applications (11)

Application Number Title Priority Date Filing Date
CN201710486397.3A Active CN107164379B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting VEGFA target gene mRNA expression and its set composition
CN201710754585.XA Pending CN107460197A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of COPS5 target genes mRNA expression
CN201710600427.9A Pending CN107400669A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of HIF1A target genes mRNA expression
CN201710754579.4A Pending CN107446925A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of ERBB3 target genes mRNA expression
CN201710488014.6A Active CN107164381B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting KRAS target gene mRNA expression and its set composition
CN201710600428.3A Active CN107201367B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting TP53 target gene mRNA expression and its set composition
CN201710601646.9A Active CN107177598B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting mRNA expression of BIRC5 target gene and its composition set
CN201710754584.5A Active CN107365771B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting CTNNB1 target gene mRNA expression and its set composition
CN201610687850.2A Pending CN106047879A (en) 2016-08-18 2016-08-18 Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof
CN201710486399.2A Active CN107164380B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting expression of EIF4E target gene mRNA and its composition set
CN201710601637.XA Active CN107177597B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting P65 target gene mRNA expression and its set composition

Family Applications Before (7)

Application Number Title Priority Date Filing Date
CN201710486397.3A Active CN107164379B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting VEGFA target gene mRNA expression and its set composition
CN201710754585.XA Pending CN107460197A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of COPS5 target genes mRNA expression
CN201710600427.9A Pending CN107400669A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of HIF1A target genes mRNA expression
CN201710754579.4A Pending CN107446925A (en) 2016-08-18 2016-08-18 For suppressing the oligonucleotide molecule and its composition set of ERBB3 target genes mRNA expression
CN201710488014.6A Active CN107164381B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting KRAS target gene mRNA expression and its set composition
CN201710600428.3A Active CN107201367B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting TP53 target gene mRNA expression and its set composition
CN201710601646.9A Active CN107177598B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting mRNA expression of BIRC5 target gene and its composition set

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610687850.2A Pending CN106047879A (en) 2016-08-18 2016-08-18 Oligonucleotide molecule used for inhibiting expression of mRNA of target gene and composition set thereof
CN201710486399.2A Active CN107164380B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting expression of EIF4E target gene mRNA and its composition set
CN201710601637.XA Active CN107177597B (en) 2016-08-18 2016-08-18 Oligonucleotide molecule for inhibiting P65 target gene mRNA expression and its set composition

Country Status (1)

Country Link
CN (11) CN107164379B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106480098A (en) * 2016-11-08 2017-03-08 同济大学苏州研究院 Targeting VEGFA gene RNA interference recombinant lentivirus vector and its construction method
CN108182346B (en) * 2016-12-08 2021-07-30 杭州康万达医药科技有限公司 Establishment method and application of machine learning model for predicting toxicity of siRNA to certain cells
EP3825321A4 (en) * 2018-07-20 2022-06-15 Guangzhou Ribobio Co., Ltd. Nucleic acid unit, polymeric nucleic acid and use thereof
CN109371054B (en) * 2018-09-16 2022-04-08 云南省烟草农业科学研究院 Method for breeding tobacco plant with lasting resistance to potato virus Y
CN110144350A (en) * 2019-05-15 2019-08-20 基诺泰康生物科技(北京)有限公司 The siRNA and its application in inhibition scar is formed that one species specificity inhibits CTGF gene expression
CN112111488A (en) * 2019-06-21 2020-12-22 苏州吉玛基因股份有限公司 siRNA modifier and application thereof in inhibiting angiogenesis
CN111534520A (en) * 2020-05-27 2020-08-14 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） Construction and application of lentivirus and recombinant vector for specifically inhibiting K-ras gene expression
KR20230043195A (en) * 2020-08-04 2023-03-30 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 Modified siRNAs with reduced off-target activity
CN113373177A (en) * 2021-05-06 2021-09-10 南方医科大学 Method for improving curative effect of glioblastoma temozolomide
CN114875065B (en) * 2022-05-06 2023-10-27 广东医科大学 Design and application of eIF4E/c-Myc gene positive feedback loop self-control shRNA silencing vector
CN117384907B (en) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 siRNA molecule for inhibiting PCSK9 expression and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068980A (en) * 2010-08-02 2013-04-24 默沙东公司 Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795422B2 (en) * 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
CN100558893C (en) * 2003-09-18 2009-11-11 Isis药物公司 The adjusting that eIF4E expresses
PL378857A1 (en) * 2006-01-31 2007-08-06 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Double twisted oligonucleotides interfering with mRNA of gene WNT1 (siRNA) used in order to inhibit polypheration of tumour cells
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CN101199858A (en) * 2007-10-18 2008-06-18 广州拓谱基因技术有限公司 Multiple target point small interference RNA cocktail agent for treating ophthalmic disease and preparing method thereof
EP2281041B1 (en) * 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Silencing of csn5 gene expression using interfering rna
EP4124657A3 (en) * 2009-04-03 2023-05-03 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
CN101897982A (en) * 2009-05-31 2010-12-01 苏州圣诺生物医药技术有限公司 SiRNA medicinal composition for treating cancers
WO2011038160A2 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
EP2550001B1 (en) * 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
CN103429254A (en) * 2010-10-11 2013-12-04 南加利福尼亚大学 Fragment of secreted heat shock protein-90alpha (Hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors
KR101390966B1 (en) * 2010-12-30 2014-06-30 주식회사 삼양바이오팜 siRNA for inhibition of Hif1α expression and anticancer composition containing the same
LT2791160T (en) * 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
CN103555731A (en) * 2013-11-08 2014-02-05 湖南莱拓福生物科技有限公司 Ser536 phosphorylated gene of NF-kB RelA/p65 and use thereof
CN104450709B (en) * 2014-11-28 2018-06-05 广州市锐博生物科技有限公司 Inhibit nucleic acid oligomer and its application of HMMR genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068980A (en) * 2010-08-02 2013-04-24 默沙东公司 Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
于媛: "RNAi技术沉默VEGF-C基因对小鼠4T1细胞生物学行为的影响", 《滨州医学院学报》 *
唐德平等: "siRNA脱靶效应类型与规避策略", 《中国生物工程杂志》 *
孙莉萍: "siRNA的化学修饰和临床应用", 《生命的化学》 *
许秀娥: "KDR siRNA对乳癌细胞凋亡和NES1与RUNX3基因甲基化影响", 《青岛大学医学院学报》 *

Also Published As

Publication number Publication date
CN107177597A (en) 2017-09-19
CN107164381A (en) 2017-09-15
CN107365771B (en) 2020-11-10
CN107201367B (en) 2019-12-27
CN107177597B (en) 2019-12-27
CN107446925A (en) 2017-12-08
CN107164380A (en) 2017-09-15
CN106047879A (en) 2016-10-26
CN107400669A (en) 2017-11-28
CN107177598B (en) 2019-12-27
CN107460197A (en) 2017-12-12
CN107201367A (en) 2017-09-26
CN107177598A (en) 2017-09-19
CN107164379B (en) 2020-06-02
CN107164381B (en) 2020-04-14
CN107164379A (en) 2017-09-15
CN107164380B (en) 2020-06-09

Similar Documents

Publication Publication Date Title
CN107365771A (en) For suppressing the oligonucleotide molecule and its composition set of CTNNB1 target genes mRNA expression
You et al. Noncoding RNA small nucleolar RNA host gene 1 promote cell proliferation in nonsmall cell lung cancer
Rose MicroRNA “Sponge”: Proof of Concept for a Novel MicroRNA Target Identification Technique
Yang et al. CircRNA_100876 promote proliferation and metastasis of breast cancer cells through adsorbing microRNA-361-3p in a sponge form.
Mashanov et al. Myc regulates programmed cell death and radial glia dedifferentiation after neural injury in an echinoderm
WO2012006181A2 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
Sekar et al. Therapeutic evaluation of microRNAs by molecular imaging
Wan et al. A super-enhancer driven by FOSL1 controls miR-21-5p expression in head and neck squamous cell carcinoma
US8470998B2 (en) Positive controls for expression modulating experiments
CN106244590B (en) Modified siRNA molecule, RNAi molecule mixture and its application
Diermeier et al. Antisense oligonucleotide-mediated knockdown in mammary tumor organoids
RU2385939C1 (en) Genetic makers attacking six new rna interference targets in transcripts of human immunodeficiency virus type 1 and suppressing virus reproduction in human cells
CN106282185B (en) Complete siRNA for inhibiting expression of clusterin gene and application thereof
WO2016145608A1 (en) Small activating rna, manufacturing method and application thereof
CN106636084A (en) Novel shRNA expression vector, preparation and applications thereof
Zhao et al. Low-density small extracellular vesicles in bovine follicular fluid carrying let-7i target FASLG to inhibit granulosa cells apoptosis
CN115161392B (en) Application of TMEM144 in preparation of tumor drugs
CN101935651A (en) siRNA module of targeted Survivin gene and application thereof
Roberts et al. Gene regulation by small RNAs
Ålander Designing strategies to induce miRNA strand selection
Jiang et al. FAM224A/hsa-mir-139/RAD54B is a Competing Endogenous RNA Network that may Serve as a New Prognostic Factor and Treatment Target for Liver Cancer
Shah Non-coding RNAs in ovarian cancer
CN117838866A (en) Smart size for inhibiting proliferation of liver cancer cells and application thereof
CN101935649A (en) SiRNA (Small Interfering RNA) molecule capable of suppressing Survivin expression and application thereof
Shi Regulation of EMT and metastasis by mutual inhibition of AP4 and miR-15a/16-1 in colorectal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210615

Address after: 510530 unit 101, building B, No.7, Houda street, Huangpu District, Guangzhou City, Guangdong Province

Patentee after: GUANGZHOU RIBOBIO Co.,Ltd.

Patentee after: Agna biopharmaceutical Co.,Ltd.

Address before: 510663 C3-13, innovation building, 182 science Avenue, Guangzhou Development Zone, Guangzhou City, Guangdong Province

Patentee before: GUANGZHOU RIBOBIO Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211123

Address after: 510530 unit 101, building B, No.7, Houda street, Huangpu District, Guangzhou City, Guangdong Province

Patentee after: Agna biopharmaceutical Co.,Ltd.

Address before: 510530 unit 101, building B, No.7, Houda street, Huangpu District, Guangzhou City, Guangdong Province

Patentee before: GUANGZHOU RIBOBIO Co.,Ltd.

Patentee before: Agna biopharmaceutical Co., Ltd